205252-59-1|UAB30|(2E,4E,6E)-8-((E)-3,4-dihydronaphthalen-1(2H)-ylidene)-3,7-dimethylocta-2,4,6-trienoic acid|-范德生物科技公司

UAB30

NMR下载 COA and HPLC MSDS下载
names：
(2E,4E,6E)-8-((E)-3,4-dihydronaphthalen-1(2H)-ylidene)-3,7-dimethylocta-2,4,6-trienoic acid
CAS号：
205252-59-1
MDL Number：
MF(分子式)： C20H22O2 MW(分子量)： 294.39
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(2E,4E,6E)-8-((E)-3,4-dihydronaphthalen-1(2H)-ylidene)-3,7-dimethylocta-2,4,6-trienoic acid
英文别名	9cUAB30, 9-cis UAB30, (all-E)-UAB 30, all-trans-UAB 30, UAB30, UAB-30, UAB 30; 9-cis-UAB30.
CAS号	205252-59-1
SMILES	O=C(O)/C=C(C)/C=C/C=C(C)/C=C1CCCC2=C\1C=CC=C2
Inchi	InChI=1S/C20H22O2/c1-15(7-5-8-16(2)14-20(21)22)13-18-11-6-10-17-9-3-4-12-19(17)18/h3-5,7-9,12-14H,6,10-11H2,1-2H3,(H,21,22)/b8-5+,15-7+,16-14+,18-13+
InchiKey	PPGNMFUMZSAZCW-FRCHHHHOSA-N
分子式 Formula	C20H22O2
分子量 Molecular Weight	294.39
闪点 FP
熔点 Melting point
沸点 Boiling point
Polarizability极化度
密度 Density
蒸汽压 Vapor Pressure
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	UAB30(CAS:205252-59-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	UAB30, also known 9cUAB30 or 9-cis-UAB30, is conformationally defined retinoic acid analogue, and is a potent, selective and low toxicity of specific ligand for the retinoid X receptor.. UAB30 down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells. 9-cis-UAB30 is a potential chemopreventative agent that has been shown to be effective on many different types of tumors.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Atigadda VR, Xia G, Desphande A, Boerma LJ, Lobo-Ruppert S, Grubbs CJ, Smith CD, Brouillette WJ, Muccio DD. Methyl substitution of a rexinoid agonist improves potency and reveals site of lipid toxicity. J Med Chem. 2014 Jun 26;57(12):5370-80. doi: 10.1021/jm5004792. Epub 2014 Jun 5. PubMed PMID: 24801499; PubMed Central PMCID: PMC4216212.

[2]Boerma LJ, Xia G, Qui C, Cox BD, Chalmers MJ, Smith CD, Lobo-Ruppert S, Griffin PR, Muccio DD, Renfrow MB. Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain. J Biol Chem. 2014 Jan 10;289(2):814-26. doi: 10.1074/jbc.M113.476861. Epub 2013 Nov 1. PubMed PMID: 24187139; PubMed Central PMCID: PMC3887207.

[3] Vedell PT, Lu Y, Grubbs CJ, Yin Y, Jiang H, Bland KI, Muccio DD, Cvetkovic D, You M, Lubet R. Effects on gene expression in rat liver after administration of RXR agonists: UAB30, 4-methyl-UAB30, and Targretin (Bexarotene). Mol Pharmacol. 2013 Mar;83(3):698-708. doi: 10.1124/mol.112.082404. Epub 2013 Jan 4. PubMed PMID: 23292798; PubMed Central PMCID: PMC3583492.

[4] Lindeblad M, Kapetanovic IM, Kabirov KK, Dinger N, Mankovskaya I, Morrisey R, Martín-Jiménez T, Lyubimov A. Assessment of oral toxicity and safety of 9-cis-UAB30, a potential chemopreventive agent, in rat and dog studies. Drug Chem Toxicol. 2011 Jul;34(3):300-10. doi: 10.3109/01480545.2010.536771. PubMed PMID: 21649485.

[5] Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE. A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers. Cancer Prev Res (Phila). 2010 Dec;3(12):1565-70. doi: 10.1158/1940-6207.CAPR-10-0149. PubMed PMID: 21149332; PubMed Central PMCID: PMC3204611.

6: Kapetanovic IM, Horn TL, Johnson WD, Cwik MJ, Detrisac CJ, McCormick DL. Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention. Int J Toxicol. 2010 Mar-Apr;29(2):157-64. doi: 10.1177/1091581809360070. PubMed PMID: 20335511.7: Jiang W, Deng W, Bailey SK, Nail CD, Frost AR, Brouillette WJ, Muccio DD, Grubbs CJ, Ruppert JM, Lobo-Ruppert SM. Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid. Cancer Biol Ther. 2009 Feb;8(3):289-98. Epub 2009 Feb 21. PubMed PMID: 19197145; PubMed Central PMCID: PMC2776760.8: Jackson JP, Kabirov KK, Kapetanovic IM, Lyubimov A. In vitro assessment of P450 induction potential of novel chemopreventive agents SR13668, 9-cis-UAB30, and pentamethychromanol in primary cultures of human hepatocytes. Chem Biol Interact. 2009 May 15;179(2-3):263-72. doi: 10.1016/j.cbi.2008.12.005. Epub 2008 Dec 16. PubMed PMID: 19135037.9: Gorman GS, Coward L, Kerstner-Wood C, Cork L, Kapetanovic IM, Brouillette WJ, Muccio DD. In vitro metabolic characterization, phenotyping, and kinetic studies of 9cUAB30, a retinoid X receptor-specific retinoid. Drug Metab Dispos. 2007 Jul;35(7):1157-64. Epub 2007 Apr 19. PubMed PMID: 17446266.10: Hansen NJ, Wylie RC, Phipps SM, Love WK, Andrews LG, Tollefsbol TO. The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells. Int J Oncol. 2007 Mar;30(3):641-50. PubMed PMID: 17273765; PubMed Central PMCID: PMC2435481.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开